These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
772 related items for PubMed ID: 32593310
1. BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features. Shi C, Cao J, Shi T, Liang M, Ding C, Lv Y, Zhang W, Li C, Gao W, Wu G, Man J. World J Surg Oncol; 2020 Jun 27; 18(1):145. PubMed ID: 32593310 [Abstract] [Full Text] [Related]
3. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. Gao J, Ma XP, Deng FS, Jiang L, Jia WD, Li M. Pathol Oncol Res; 2020 Jul 27; 26(3):1833-1841. PubMed ID: 31758408 [Abstract] [Full Text] [Related]
6. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L. Eur J Endocrinol; 2013 May 27; 168(5):675-81. PubMed ID: 23416953 [Abstract] [Full Text] [Related]
10. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H. Endocrine; 2012 Oct 27; 42(2):404-10. PubMed ID: 22426956 [Abstract] [Full Text] [Related]
11. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases. Zarkesh M, Zadeh-Vakili A, Akbarzadeh M, Nozhat Z, Fanaei SA, Hedayati M, Azizi F. Life Sci; 2019 Apr 15; 223():166-173. PubMed ID: 30890403 [Abstract] [Full Text] [Related]
13. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J. PLoS One; 2016 Apr 15; 11(12):e0167414. PubMed ID: 27936049 [Abstract] [Full Text] [Related]
15. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, Al Kaabi J. PLoS One; 2020 Apr 15; 15(4):e0231341. PubMed ID: 32315324 [Abstract] [Full Text] [Related]
16. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Tao Y, Wang F, Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Zhao S, Wang Y, Xing M. J Clin Endocrinol Metab; 2021 Oct 21; 106(11):3228-3238. PubMed ID: 34273152 [Abstract] [Full Text] [Related]
18. Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis. Song JY, Sun SR, Dong F, Huang T, Wu B, Zhou J. Curr Med Sci; 2018 Oct 21; 38(5):785-797. PubMed ID: 30341513 [Abstract] [Full Text] [Related]
19. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma]. Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY. Zhonghua Zhong Liu Za Zhi; 2017 May 23; 39(5):361-366. PubMed ID: 28535653 [Abstract] [Full Text] [Related]